Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Blood Advances|February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformationKatharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
The Lancet. Oncology|July 8, 2022
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyLihua E Budde, Laurie H Sehn, Matthew Matasar, et al.
American Journal of Hematology|March 20, 2026
Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary AnalysisNancy L Bartlett, Laurie H Sehn, Sarit Assouline, et al.
European Journal of Haematology|December 20, 2022
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryJames Nguyen, Cameron Wellard, Eliza Chung, et al.
Blood|October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesLaurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2025
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION StudyAdrian Minson, Emma Verner, Pratyush Giri, et al.
Leukemia & Lymphoma|October 7, 2020
Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter studyMansi Bhurani, Lorenz Admojo, Carrie Van Der Weyden, et al.
The Lancet. Oncology|July 13, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trialJustin Ferdinandus, Gundolf Schneider, Alden Moccia, et al.
The New England Journal of Medicine|June 3, 2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Mats Jerkeman, et al.
Pageof 3